This thing has been around forever and never brought in a dime. They are on what seems to be their last legs. About to get booted from AMEX, cancelled the most exciting part of their R&D, still have absolutely no money, etc. They are existing month to month. Halting the OVA development is a good idea, but that was the most interesting thing they were doing IMO. They feel they can focus on the drugs and bring them to market faster than the OVA technology is going to catch on. They pretty much asked for someone to license it in the PR.
Market Data 
Markets 
AI
